Histology of good risk non-seminomatous germ cell tumour (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after four cycles of etoposide and cisplatin (Epx4)

被引：0
|
作者：
Patel, MI [1 ]
Beck, SDW [1 ]
Sheinfeld, J [1 ]
机构：
[1] Univ Sydney, Sydney, NSW 2006, Australia
来源：
BJU INTERNATIONAL | 2005年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [21] How to do an open midline extraperitoneal bilateral retroperitoneal lymph node dissection for non-seminomatous germ cell tumour
    Parkin, Cameron James
    Sharma, Aditya
    Winter, Matthew
    ANZ JOURNAL OF SURGERY, 2023, 93 (1-2) : 337 - 338
  • [22] Validation of the two best models to predict "benign" pathohistology in patients with advanced nonseminomatous germ cell tumors (NSGCT) undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND)
    Nestler, Tim
    Paffenholz, Pia
    Baessler, Bettina
    Hellmich, Martin
    Hiester, Andreas
    Nini, Alessandro
    Pfister, David
    Albers, Peter
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Retroperitoneal laparoscopic lymph node dissection for staging non-seminomatous germ cell tumors before and after chemotherapy
    Rassweiler, JJ
    Henkel, TO
    Stock, C
    Seemann, O
    Frede, T
    Alken, P
    LYMPHOLOGY, 1996, 29 (01) : 36 - 44
  • [24] Robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumour in a centralised post-chemotherapy surgical practice
    Thomas, B.
    Lee, E.
    Coret, M.
    BJU INTERNATIONAL, 2018, 121 : 27 - 28
  • [25] Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors
    Muramaki, M
    Hara, I
    Miyake, H
    Yamada, Y
    Okada, H
    Kamidono, S
    INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (09) : 763 - 767
  • [26] Viable germ cell tumor (GCT) identified at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND): The significance of risk assignment and adjuvant chemotherapy
    Karanikolas, NT
    Serio, A
    Vickers, AJ
    Carver, BS
    Stephenson, AJ
    Bosl, GJ
    Joel, S
    JOURNAL OF UROLOGY, 2006, 175 (04): : 191 - 191
  • [27] Risk of distant metastasis following retroperitoneal lymph-node dissection (RPLND) alone in clinical stage I (CS I) non-seminomatous germ cell testicular tumours (NSGCTTS)
    Nicolai, Nicola
    Miceli, Rosalba
    Pizzocaro, Giorgio
    Piva, Luigi
    Biasoni, Davide
    Torelli, Tullio
    Milani, Angelo
    Salvioni, Roberto
    JOURNAL OF UROLOGY, 2008, 179 (04): : 176 - 176
  • [28] Risk of distant metastasis following retroperitoneal lymph-node dissection (RPLND) alone in clinical stage I (CS I) non-seminomatous germ cell testicular tumours (NSGCTTS)
    Nicolai, N.
    Miceli, R.
    Pizzocaro, G.
    Piva, L.
    Biasoni, D.
    Torelli, T.
    Salvioni, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 84 - 84
  • [29] The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors (GCTs)
    Taza, Fadi
    Chovanec, Michal
    Snavely, Anna
    Adra, Nabil
    Hanna, Nasser H.
    Cary, Clint
    Masterson, Timothy A.
    Einhorn, Lawrence H.
    Albany, Costantine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour, a multicenter retrospective cohort study
    Antonelli, L.
    Heidenreich, A.
    Bagrodia, A.
    Branger, N.
    Cazzaniga, W.
    Clinton, T. N.
    Daneshmand, S.
    Djaladat, H.
    Eggener, S.
    Hamilton, R. J.
    Ho, M.
    Sexton, W. J.
    Nazzani, S.
    Nicol, D.
    Nicolai, N.
    Olson, K.
    Paffenholz, P.
    Porter, J.
    Singla, N.
    Stroup, S. P.
    Tachibana, I
    Terbuch, A.
    Cary, C.
    Fankhauser, C. D.
    EUROPEAN UROLOGY, 2024, 85 : S722 - S723
12345